MeSH term
Frequency | Condition_Probility | Adult | 14 | 0.0 |
Aged | 11 | 0.0 |
Drug Resistance, Neoplasm | 16 | 3.0 |
Female | 33 | 0.0 |
Humans | 176 | 0.0 |
Male | 19 | 0.0 |
Middle Aged | 11 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 127 | 0.0 |
Treatment Outcome | 5 | 0.0 |
Acute Disease | 9 | 0.0 |
Adolescent | 5 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Cytarabine/*therapeutic use | 5 | 33.0 |
Cytidine Deaminase/analysis | 2 | 100.0 |
Disease-Free Survival | 3 | 0.0 |
*Drug Resistance, Neoplasm | 6 | 3.0 |
Equilibrative Nucleoside Transporter 1 | 2 | 25.0 |
Retrospective Studies | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
Blotting, Western | 9 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Cyclosporine/pharmacology | 3 | 1.0 |
Daunorubicin/pharmacology | 2 | 8.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Mitochondria/*enzymology | 2 | 1.0 |
Nucleosides/metabolism | 2 | 22.0 |
P-Glycoprotein/metabolism | 3 | 4.0 |
Phosphorylation | 34 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Tumor Cells, Cultured | 39 | 0.0 |
Animals | 41 | 0.0 |
Cell Death | 2 | 0.0 |
Cell Line | 21 | 0.0 |
Cytarabine/*pharmacology | 10 | 27.0 |
Cytidine Deaminase/metabolism | 4 | 36.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Deoxycytidine/*analogs & derivatives/*pharmacology | 5 | 35.0 |
Deoxycytidine Kinase/*genetics | 12 | 100.0 |
Genetic Vectors | 5 | 0.0 |
Mice | 26 | 0.0 |
Phenotype | 3 | 0.0 |
Thymidine Kinase/metabolism | 9 | 30.0 |
Antimetabolites, Antineoplastic/*pharmacology | 8 | 8.0 |
Blotting, Northern | 4 | 0.0 |
Drug Screening Assays, Antitumor | 11 | 3.0 |
Prodrugs/*pharmacology | 4 | 33.0 |
Transduction, Genetic | 3 | 0.0 |
Phosphotransferases/*metabolism | 4 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 34 | 0.0 |
T-Lymphocytes/enzymology | 4 | 10.0 |
Transfection | 8 | 0.0 |
Survival Analysis | 3 | 0.0 |
Child | 11 | 0.0 |
Child, Preschool | 8 | 0.0 |
DNA, Complementary/analysis | 3 | 1.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Infant | 3 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/*genetics | 2 | 6.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Cell Survival/drug effects | 3 | 0.0 |
Drug Resistance | 7 | 1.0 |
Rats | 8 | 0.0 |
Tumor Cells, Cultured/drug effects | 7 | 1.0 |
Anti-HIV Agents/*pharmacology | 2 | 1.0 |
Cell Division | 4 | 0.0 |
Cytarabine/pharmacology | 4 | 8.0 |
Deoxycytidine Kinase/metabolism | 17 | 89.0 |
HIV-1/*drug effects/physiology | 2 | 2.0 |
Virus Replication/*drug effects | 3 | 1.0 |
Phylogeny | 2 | 0.0 |
Purines/metabolism | 3 | 16.0 |
Pyrimidines/metabolism | 3 | 21.0 |
Sequence Alignment | 3 | 0.0 |
Substrate Specificity | 29 | 1.0 |
Cell Division/drug effects | 12 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Deoxycytidine Kinase/*genetics/metabolism | 3 | 100.0 |
Mice, Nude | 5 | 0.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Antineoplastic Agents/*pharmacokinetics/pharmacology | 2 | 66.0 |
Biological Transport | 3 | 0.0 |
Comparative Study | 24 | 0.0 |
Molecular Sequence Data | 25 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Stereoisomerism | 13 | 3.0 |
Tritium | 4 | 1.0 |
Deoxycytidine Kinase/chemistry/*metabolism | 2 | 100.0 |
Deoxycytidine Kinase/*chemistry | 4 | 100.0 |
Protein Conformation | 6 | 0.0 |
Apoptosis/drug effects | 4 | 0.0 |
*Drug Resistance, Multiple | 3 | 2.0 |
HIV-1/drug effects | 5 | 12.0 |
Lymphocytes/drug effects/virology | 2 | 100.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
Solubility | 3 | 0.0 |
Structure-Activity Relationship | 11 | 0.0 |
Virus Replication/drug effects | 3 | 1.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/*methods | 2 | 3.0 |
Sensitivity and Specificity | 2 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Deoxycytidine Kinase/*metabolism | 35 | 97.0 |
Enzyme Activation | 8 | 0.0 |
Sodium Fluoride/*pharmacology | 2 | 50.0 |
Time Factors | 5 | 0.0 |
Antineoplastic Agents/*pharmacology | 10 | 1.0 |
Arabinonucleosides/*pharmacology | 3 | 75.0 |
DNA, Neoplasm/metabolism | 3 | 2.0 |
5'-Nucleotidase/metabolism | 2 | 33.0 |
DNA Topoisomerases, Type II/metabolism | 2 | 9.0 |
Deoxycytosine Nucleotides/metabolism | 3 | 60.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Leukemia, Myelocytic, Acute/drug therapy/enzymology/*genetics | 2 | 66.0 |
Recurrence | 3 | 0.0 |
Adenosine Triphosphate/metabolism | 8 | 1.0 |
Antimetabolites, Antineoplastic/pharmacology | 6 | 7.0 |
Arabinofuranosylcytosine Triphosphate/metabolism | 4 | 80.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Drug Synergism | 5 | 0.0 |
Guanosine Triphosphate/metabolism | 2 | 0.0 |
Nucleoside Deaminases/metabolism | 4 | 100.0 |
Uridine Triphosphate/metabolism | 5 | 71.0 |
Coumarins/*chemical synthesis/chemistry/pharmacology | 2 | 100.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Virus Replication | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 3 | 1.0 |
Leukemia, Myeloid/*pathology | 2 | 3.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
HL-60 Cells | 6 | 1.0 |
Lymphocytes/*drug effects/enzymology | 3 | 27.0 |
Phosphoprotein Phosphatase/metabolism | 2 | 2.0 |
Base Sequence | 19 | 0.0 |
Binding Sites | 6 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Kinetics | 26 | 0.0 |
Antimetabolites, Antineoplastic/metabolism/*pharmacology | 3 | 42.0 |
Cytarabine/metabolism/*pharmacology | 3 | 75.0 |
Gene Expression | 3 | 0.0 |
Mice, Inbred ICR | 2 | 0.0 |
Mice, SCID | 3 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Deoxycytidine Kinase/deficiency/*genetics/metabolism | 2 | 100.0 |
Drug Resistance, Neoplasm/*genetics | 4 | 4.0 |
Ovarian Neoplasms/pathology | 2 | 6.0 |
Antineoplastic Agents, Phytogenic/*therapeutic use | 2 | 6.0 |
DNA, Complementary/genetics | 3 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Half-Life | 4 | 0.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Cell Division/drug effects/physiology | 2 | 0.0 |
Neoplasm Transplantation | 5 | 0.0 |
Cytarabine/*metabolism | 3 | 100.0 |
Gene Deletion | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 2 | 2.0 |
Cloning, Molecular | 6 | 0.0 |
Deoxycytidine Kinase/genetics/*metabolism | 4 | 100.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Thymidine Kinase/genetics/*metabolism | 2 | 33.0 |
Antimetabolites, Antineoplastic/*therapeutic use | 4 | 10.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Nucleosides/*therapeutic use | 2 | 28.0 |
Models, Molecular | 3 | 0.0 |
Biotransformation | 3 | 0.0 |
DNA, Neoplasm/biosynthesis | 3 | 2.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Deoxyadenosines/chemistry | 2 | 50.0 |
Deoxyguanosine/analogs & derivatives/chemistry | 2 | 100.0 |
In Vitro | 6 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 6 | 7.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Deoxycytidine/*analogs & derivatives/pharmacology | 7 | 28.0 |
Deoxycytidine Kinase/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Drug Design | 5 | 1.0 |
Leukemia/*enzymology | 3 | 23.0 |
Methylation | 4 | 0.0 |
Thymidine Kinase/antagonists & inhibitors/*metabolism | 2 | 66.0 |
DNA Primers | 3 | 0.0 |
HIV-1/*drug effects | 2 | 1.0 |
Thymidine Kinase/*metabolism | 7 | 46.0 |
Lactones/*pharmacology | 2 | 6.0 |
Adenosine Triphosphate/chemistry/metabolism | 2 | 20.0 |
Uridine Triphosphate/chemistry/metabolism | 2 | 100.0 |
Cladribine/pharmacology | 2 | 25.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Leukemia/pathology | 2 | 6.0 |
Anti-HIV Agents/*chemical synthesis/chemistry/pharmacology | 2 | 18.0 |
Molecular Conformation | 2 | 0.0 |
Molecular Structure | 3 | 0.0 |
Zidovudine/pharmacology | 2 | 3.0 |
Deoxycytidine Kinase/biosynthesis/*genetics | 2 | 100.0 |
Cladribine/*pharmacology | 6 | 60.0 |
Cytoplasm/enzymology | 3 | 3.0 |
Protein p53/metabolism | 2 | 0.0 |
*CpG Islands | 2 | 2.0 |
*DNA Methylation | 3 | 0.0 |
Deoxycytidine Kinase/genetics | 6 | 100.0 |
Leukemia, Myelocytic, Acute/*genetics | 2 | 1.0 |
Catalysis | 2 | 0.0 |
Antiviral Agents/*metabolism | 2 | 16.0 |
Cytidine Deaminase/*metabolism | 2 | 18.0 |
Cell Extracts | 2 | 1.0 |
Cladribine/therapeutic use | 2 | 33.0 |
Deoxycytidine/metabolism | 5 | 62.0 |
Thymidine/metabolism | 4 | 1.0 |
Drug Resistance, Neoplasm/genetics | 3 | 4.0 |
Cell Cycle | 3 | 0.0 |
Leukocytes, Mononuclear/*enzymology | 2 | 8.0 |
Zidovudine/metabolism | 2 | 40.0 |
Deoxycytidine/*analogs & derivatives/therapeutic use | 2 | 18.0 |
Nucleoside Deaminases/*metabolism | 3 | 60.0 |
HL-60 Cells/drug effects/enzymology | 2 | 50.0 |
Leukemia | 2 | 2.0 |
Tonsil | 2 | 9.0 |
Spleen/enzymology | 4 | 12.0 |
Gene Expression Regulation, Enzymologic/drug effects | 3 | 1.0 |
Lymphocytes/*enzymology | 3 | 4.0 |
Clinical Trials, Phase I | 2 | 3.0 |
English Abstract | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Cell Line, Tumor | 6 | 0.0 |
Cladribine/*metabolism | 2 | 100.0 |
Deoxycytidine/*analogs & derivatives/metabolism/*pharmacology | 4 | 100.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Cytidine Triphosphate/metabolism | 2 | 33.0 |
Dimerization | 2 | 0.0 |
Recombinant Proteins/chemistry/isolation & purification/metabolism | 2 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Cytarabine/therapeutic use | 3 | 7.0 |
Daunorubicin/therapeutic use | 2 | 14.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Deoxycytidine Kinase/*biosynthesis | 3 | 100.0 |
Mutation | 3 | 0.0 |
Antimetabolites, Antineoplastic/*metabolism | 2 | 33.0 |
DNA-Directed DNA Polymerase/metabolism | 3 | 9.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Methotrexate/pharmacology | 2 | 2.0 |
Verapamil/pharmacology | 2 | 2.0 |
Protein Structure, Secondary | 2 | 0.0 |
Radioisotope Dilution Technique | 2 | 6.0 |
DNA Polymerase II/metabolism | 2 | 11.0 |
Deoxycytosine Nucleotides/pharmacology | 3 | 75.0 |
Cladribine/metabolism | 3 | 100.0 |
DNA Mutational Analysis | 3 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
Leukemia, Hairy Cell/enzymology | 2 | 100.0 |
Leukemia, Lymphocytic, Chronic/enzymology | 2 | 50.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Brain Neoplasms/drug therapy | 2 | 33.0 |
Neoplasms/*drug therapy | 2 | 1.0 |
Prognosis | 2 | 0.0 |
Neoplasms/*enzymology | 2 | 5.0 |
Leukocytes/*enzymology | 2 | 3.0 |
Phosphates/metabolism | 2 | 2.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Ligands | 2 | 0.0 |
DNA Repair | 2 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/genetics/*metabolism | 2 | 15.0 |
Deoxyadenine Nucleotides/chemistry/*metabolism | 2 | 66.0 |
Deoxycytidine Kinase/*chemistry/*metabolism | 2 | 100.0 |
Antimetabolites, Antineoplastic/therapeutic use | 2 | 9.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Leukemia/*metabolism | 2 | 4.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Biopsy | 2 | 0.0 |
DCMP Deaminase/genetics | 2 | 100.0 |
Cattle | 2 | 0.0 |
Leukemia, Myeloid/drug therapy/*enzymology | 2 | 66.0 |
Enzyme Activation/radiation effects | 2 | 8.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
Drug Therapy, Combination | 2 | 0.0 |
